Alexei Kharitonenkov

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
    Alexei Kharitonenkov
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Endocrinology 148:774-81. 2007
  2. doi Fibroblast growth factor 21 corrects obesity in mice
    Tamer Coskun
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Endocrinology 149:6018-27. 2008
  3. ncbi FGF21: a novel prospect for the treatment of metabolic diseases
    Alexei Kharitonenkov
    Eli Lilly and Co, Lilly Research Laboratories, Biotechnology Discovery Research, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Investig Drugs 10:359-64. 2009
  4. pmc FGF21 requires βklotho to act in vivo
    Andrew C Adams
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    PLoS ONE 7:e49977. 2012
  5. pmc Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
    Alexei Kharitonenkov
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, United States of America
    PLoS ONE 8:e58575. 2013
  6. pmc FGF-21 as a novel metabolic regulator
    Alexei Kharitonenkov
    Lilly Research Laboratories, Division of Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Invest 115:1627-35. 2005
  7. doi FGFs and metabolism
    Alexei Kharitonenkov
    Eli Lilly and Company, Lilly Research Laboratories, Biotechnology Discovery Research, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Pharmacol 9:805-10. 2009
  8. ncbi Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases
    Alexei Kharitonenkov
    BioTechology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    BioDrugs 22:37-44. 2008
  9. ncbi FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho
    Alexei Kharitonenkov
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cell Physiol 215:1-7. 2008
  10. pmc Fundamentals of FGF19 & FGF21 action in vitro and in vivo
    Andrew C Adams
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, United States of America
    PLoS ONE 7:e38438. 2012

Collaborators

Detail Information

Publications19

  1. ncbi The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
    Alexei Kharitonenkov
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Endocrinology 148:774-81. 2007
    ..These data support the development of FGF-21 for the treatment of diabetes and other metabolic diseases...
  2. doi Fibroblast growth factor 21 corrects obesity in mice
    Tamer Coskun
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    Endocrinology 149:6018-27. 2008
    ..Overall, these data suggest that FGF21 exhibits the therapeutic characteristics necessary for an effective treatment of obesity and fatty liver disease and provides novel insights into the metabolic determinants of these activities...
  3. ncbi FGF21: a novel prospect for the treatment of metabolic diseases
    Alexei Kharitonenkov
    Eli Lilly and Co, Lilly Research Laboratories, Biotechnology Discovery Research, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Investig Drugs 10:359-64. 2009
    ..The pharmacology of FGF21, molecular mechanisms contributing to the actions of this compound, and knowledge gaps to be addressed to allow further exploration of the therapeutic potential of this molecule are discussed in this review...
  4. pmc FGF21 requires βklotho to act in vivo
    Andrew C Adams
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    PLoS ONE 7:e49977. 2012
    ..Taken together our data show that KLB is a vital component of the FGF21 in vivo signaling machinery and is critically required for FGF21 action at the whole organism level...
  5. pmc Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319
    Alexei Kharitonenkov
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, United States of America
    PLoS ONE 8:e58575. 2013
    ....
  6. pmc FGF-21 as a novel metabolic regulator
    Alexei Kharitonenkov
    Lilly Research Laboratories, Division of Eli Lilly and Co, Indianapolis, Indiana 46285, USA
    J Clin Invest 115:1627-35. 2005
    ..Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes...
  7. doi FGFs and metabolism
    Alexei Kharitonenkov
    Eli Lilly and Company, Lilly Research Laboratories, Biotechnology Discovery Research, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Curr Opin Pharmacol 9:805-10. 2009
    ....
  8. ncbi Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases
    Alexei Kharitonenkov
    BioTechology Discovery Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    BioDrugs 22:37-44. 2008
    ..The specifics of FGF21 activities both in cell culture and in vivo, its potential as a target for diabetes, and insights into the molecular mechanisms of FGF21 metabolic actions will be discussed in this review...
  9. ncbi FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho
    Alexei Kharitonenkov
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cell Physiol 215:1-7. 2008
    ..All together, these results indicate that betaKlotho and FGFRs form the cognate FGF-21 receptor complex, mediating FGF-21 cellular specificity and physiological effects...
  10. pmc Fundamentals of FGF19 & FGF21 action in vitro and in vivo
    Andrew C Adams
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, United States of America
    PLoS ONE 7:e38438. 2012
    ....
  11. ncbi Different roles of N- and C- termini in the functional activity of FGF21
    Radmila Micanovic
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cell Physiol 219:227-34. 2009
    ..Our structure/function studies show that the C-terminus is important for betaKlotho interaction whereas the N-terminus likely interacts directly with FGF receptors...
  12. doi The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
    Gregory Gaich
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Cell Metab 18:333-40. 2013
    ..However, only a trend toward glucose lowering was observed. These results indicate that FGF21 is bioactive in humans and suggest that FGF21-based therapies may be effective for the treatment of selected metabolic disorders...
  13. ncbi Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling
    Julie S Moyers
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Cell Physiol 210:1-6. 2007
    ..Together these results reveal a novel synergy between two regulators of glucose homeostasis, FGF-21 and PPARgamma, and further define FGF-21 mechanism of action...
  14. doi FGF21 reloaded: challenges of a rapidly growing field
    Alexei Kharitonenkov
    Eli Lilly and Company, Diabetes Research, Indianapolis, IN 46285, USA
    Trends Endocrinol Metab 22:81-6. 2011
    ..In this paper, we focus on current challenges in the field in an attempt to provide a balanced overview of FGF21 biology and guide future research into this exciting metabolic target...
  15. pmc Circulating αKlotho influences phosphate handling by controlling FGF23 production
    Rosamund C Smith
    Biotechnology Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Clin Invest 122:4710-5. 2012
    ..These findings have important implications for the regulation of αKL and FGF23 in disorders of phosphate handling and biomineralization...
  16. doi FGF21 as a therapeutic reagent
    Yang Zhao
    Eli Lilly and Company, Indianapolis, IN, USA
    Adv Exp Med Biol 728:214-28. 2012
    ..The in vitro biology, genetic animal models and in vivo pharmacology of FGF21 will be discussed in this chapter...
  17. doi Hormone-like fibroblast growth factors and metabolic regulation
    Yun Chau Long
    Eli Lilly and Company, Lilly Research Laboratory, Lilly Corporate Center, Indianapolis Indiana 46285, USA
    Biochim Biophys Acta 1812:791-5. 2011
    ....